Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries

Rhea-AI Summary

Illumina Inc. (NASDAQ: ILMN) Launches Global Health Access Initiative to Address Barriers to Genomic Sequencing in Low- and Middle-Income Countries (LMICs)

Program aims to address key barriers to genomic sequencing in-country

SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs). The program, developed with guidance from customers, funders, and market facilitators including the nonprofit FIND, will provide reduced pricing structures for eligible sequencing products from Illumina to qualified global health funding entities and address key international logistics and supply chain challenges.

"We know that enabling countries to perform pathogen sequencing locally strengthens health systems, enables better preparedness, and empowers countries to manage their priority health threats," said Vanessa Moeder, head of Global Health at Illumina. "It also avoids costly and time-consuming shipment of samples abroad and leads to faster response times. We cannot lose time preparing for the next pandemic, and adoption of pathogen genomic surveillance in every country allows us to get ahead of infectious threats."

Currently, pricing for sequencing instruments and consumables can vary by country or region, which is challenging for funders and donors and can limit broad implementation. In the Illumina global team's experience, Moeder says, the countries or regions whose public health preparedness would most benefit from genomics often lack the resources to sustainably implement it.

To begin addressing these challenges, Illumina's Global Health Access Initiative will provide discounted prices for a range of sequencing applications, including drug resistance profiling in tuberculosis, whole-genome sequencing of emerging and reemerging viruses to monitor virus evolution and support outbreak response, broad respiratory pathogen detection for influenza-like illness surveillance, wastewater and other environmental surveillance applications to track pathogens, and antimicrobial resistances at the population level.

To simplify budgeting and procurement, Illumina's key components for these applications are available as single-part-number combination kits, encompassing library preparation reagents, sequencing reagents, and data analysis tools.

Expanding sequencing capabilities in LMICs is a long-term focus for Illumina, and it forms the foundation of collaborations with organizations like FIND and The Global Fund to Fight AIDS, Tuberculosis and Malaria. Recently, significant advances have been made in global genomic sequencing capacity: As of December 2022, 84% of World Health Organization (WHO) member states are capable of sequencing SARS-COV-2, and as of October 2023, over 16 million SARS-CoV-2 genomes have been deposited in the GISAID repository. However, geographic disparities in the ability to monitor pathogens beyond SARS-CoV-2 lead to significant gaps in the detection of emerging threats, putting global health security at risk.

"Significant sequencing capacity was built up globally during the pandemic to identify, track and monitor variants, capacity which should be leveraged to help combat multiple health challenges. Initiatives such as this are critical to help improve affordability and access to genomics in low- and middle-income countries, to ensure that every country can benefit from the technology in a scalable and sustainable manner for routine use," said Anita Suresh, Head of Genomics & Sequencing at FIND.

The WHO's global pathogen genomic surveillance strategy and guide for national implementation for genomics both recognize that pathogen sequencing is a unique and essential tool for driving preparedness for emerging and reemerging threats, and for increasing understanding of the molecular epidemiology of disease outbreaks. The organization has also issued a rapid communication highlighting how sequencing can aid the management of endemic diseases, including drug-resistant tuberculosis, an ongoing public health crisis. Genomics has recently been leveraged to detect the introduction of dengue virus type 3 genotypes to Brazil, which has important public health implications, and recent studies cite pathogen genomic sequencing as a critical tool for managing outbreaks such as Marburg virus, Ebola virus, and mpox, as well as part of a "One Health" approach to managing antimicrobial resistance.

"In an age where technology plays a crucial role in surveillance and diagnostics during pandemics, ensuring equitable access to these tools is not just a matter of fairness but a matter of global public health security," said Toni Whistler, US Centers for Disease Control detailee to The Global Fund. "The ability to monitor and diagnose diseases swiftly and accurately, without leaving vulnerable populations behind, is fundamental to our collective preparedness in the face of global health crises. The equitable access program developed and operationalized by Illumina will allow many low- and middle-income nations to participate in the future of genomics across public health and preparedness."

Learn more about the Global Health Access Initiative.

About Illumina
Illumina is improving human health by unlocking the power of the genome. In 2023 we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Salli Schwartz
858-291-6421
IR@illumina.com

Media:
David McAlpine
347-327-1336
PR@illumina.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-launches-global-health-access-initiative-to-support-acceleration-of-pathogen-sequencing-in-low--and-middle-income-countries-301985451.html

SOURCE Illumina, Inc.

FAQ

What is the Global Health Access Initiative launched by Illumina Inc.?

The Global Health Access Initiative aims to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs) by providing reduced pricing structures for eligible sequencing products from Illumina to qualified global health funding entities.

What are the key components of Illumina's Global Health Access Initiative?

The initiative will provide discounted prices for a range of sequencing applications, including drug resistance profiling in tuberculosis, whole-genome sequencing of emerging and reemerging viruses, broad respiratory pathogen detection, wastewater and environmental surveillance applications, and antimicrobial resistance tracking at the population level.

What is the significance of the Global Health Access Initiative in the context of global health security?

The initiative aims to bridge geographic disparities in pathogen monitoring capabilities, which are crucial for detecting emerging threats and enhancing global health security.

How does the WHO view pathogen sequencing in the context of global health preparedness?

The WHO recognizes pathogen sequencing as a unique and essential tool for driving preparedness for emerging and reemerging threats and increasing understanding of the molecular epidemiology of disease outbreaks.

What is the potential impact of Illumina's initiative on low- and middle-income countries' participation in genomics across public health and preparedness?

The initiative will allow many low- and middle-income nations to participate in the future of genomics across public health and preparedness, ensuring equitable access to surveillance and diagnostics tools.